Read More Pharma Industry News Lilly’s Omvoh sets a new benchmark in ulcerative colitis with four-year steroid-free remission data Eli Lilly’s Omvoh (mirikizumab-mrkz) delivers four years of steroid-free remission in ulcerative colitis patients according to LUCENT-3 data. Discover how this sets a new benchmark for IBD therapy. byVenkateshOctober 7, 2025